| Ronald C. Peterson | |
|---|---|
| Photo placeholder | |
| Affiliations | Mayo Clinic Mayo Clinic Alzheimer's Disease Research Center |
| Country | USA |
| H-index | 180 |
| ORCID | 0000-0002-4579-0510 |
| Research Focus | [Alzheimer's Disease](/diseases/alzheimers), [MCI](/diseases/mild-cognitive-impairment) |
| Mechanisms | [Amyloid](/mechanisms/amyloid-cascade), [Beta-amyloid](/mechanisms/beta-amyloid), [Clinical trials](/mechanisms/clinical-trials) |
Ronald C. Peterson is a leading researcher in Alzheimer's disease and cognitive decline, affiliated with Mayo Clinic and the Mayo Clinic Alzheimer's Disease Research Center. Their research focuses on Amyloid, Beta-amyloid, and Clinical trials, with particular emphasis on Alzheimer's Disease and Mild Cognitive Impairment (MCI)[1][2].
Peterson's work has been instrumental in advancing our understanding of the preclinical and prodromal stages of Alzheimer's disease, particularly through large-scale longitudinal studies. With an h-index of approximately 180, Peterson is one of the most cited researchers in the Alzheimer's field.
Based at Mayo Clinic, Peterson leads the Alzheimer's Disease Research Center and has played a key role in developing diagnostic criteria and therapeutic strategies for Alzheimer's disease.
Peterson's portfolio emphasizes early detection and intervention in Alzheimer's disease, with a focus on biomarker development and clinical trial design[3]. Their research has contributed significantly to understanding the natural history of MCI and AD, and to identifying individuals at risk before symptom onset[4].
The work bridges observational cohort studies and clinical trials, providing critical insights into disease progression and therapeutic efficacy.
Research conducted by Peterson utilizes:
For NeuroWiki readers, Peterson's research provides critical insights into:
Dr. Peterson's research has had direct clinical impact on Alzheimer's disease diagnosis and treatment. His work on mild cognitive impairment (MCI) has helped establish standardized diagnostic criteria now used worldwide. The Peterson classification of MCI has become a fundamental framework for early dementia detection.
Key contributions include:
Dr. Peterson has received the Metropolitan Life Foundation Award for Alzheimer's Disease Research and the American Academy of Neurology's Potamkin Prize. He is a fellow of the American Academy of Neurology and the American Association for the Advancement of Science.